Image of the human body with PET scan
Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Melbourne-based Telix Pharmaceuticals Ltd (ASX:TLX) is set to expand its manufacturing and distribution footprint in North America with the acquisition of RLS Inc – the only US radiopharmacy network which is Joint Commission-accredited.

The two companies have entered an agreement for Telix to take on RLS Inc from its parent company, RLS Group Ltd, in a move which will increase the former’s manufacturing footprint in North America, establishing a future radiometal production network to benefit the company and its strategic partners.

RLS holds 31 licensed radiopharmacies in major cities across the United States, so the acquisition will allow Telix to make use of these, developing a production and distribution network for key therapeutic and diagnostic isotopes alongside last-mile delivery of finished unit doses in relevant markets.

It is also expected that the acquisition will open the door to extensively deploy Telix’s ARTMS QUANTM Irradiation System™ (QIS™) cyclotron technology.

Managing director and group CEO Dr Christian Behrenbruch said the acquisition is part of Telix’s ongoing investment focus around vertical integration and building integrated supply chains.

“Our vision is to build a radiometal production and distribution network fit for the future. By combining the ARTMS platform and the RLS network, we can scale up the production of key isotopes and build a stable and consistent supply of PET and SPECT diagnostic tracers, along with therapeutic radiopharmaceuticals across the U.S. for the benefit of Telix, our partners and the patients we serve,” he said.

“Telix is a trusted brand, recognised for our technical expertise, product quality, scheduling flexibility and delivery reliability.

“As we grow and commercialise new products, this investment ensures we can continue to deliver to this standard, alongside our key trusted distribution partners.”

Telix shares fell on the news. At 12:04 AEST, they were trading at $19.96 – a fall of 1.75% since the market opened.

TLX by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Financials lead index higher after Trump inauguration | January 21, 2025

The local index clawed back losses throughout the afternoon as investors reacted to Trump’s impending decisions…
The Market Online Video

‘Where there’s risk, there’s reward’: Stab on asset manager the year’s first Hot Stock tip

Wealth Within senior analyst Fil Tortevski and analyst Pedro Banales have named their first HotCopper Hot Stock tip of the year,
REIT concept

Trump is banning work-from-home for Federal workers. Could our REIT index see contagion upside?

To answer the question at the top of the article, any benefit for Australian REIT stocks posed by Trump’s decision to ban work-from-home
Image of clinical researcher making notes

‘Significant’ new milestone for Recce in clinical testing of skin infection gel

Recce Pharmaceuticals Ltd has seen its share price rise more than 1% as it completes dosing…